NO332800B1 - Vaksinesammensetning egnet for behandling eller profylakse av humanpapillomavirusinfeksjoner og herpes simpleksvirusinfeksjoner - Google Patents

Vaksinesammensetning egnet for behandling eller profylakse av humanpapillomavirusinfeksjoner og herpes simpleksvirusinfeksjoner Download PDF

Info

Publication number
NO332800B1
NO332800B1 NO20021116A NO20021116A NO332800B1 NO 332800 B1 NO332800 B1 NO 332800B1 NO 20021116 A NO20021116 A NO 20021116A NO 20021116 A NO20021116 A NO 20021116A NO 332800 B1 NO332800 B1 NO 332800B1
Authority
NO
Norway
Prior art keywords
antigen
hpv
vaccine composition
vaccine
composition according
Prior art date
Application number
NO20021116A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021116D0 (no
NO20021116L (no
Inventor
Moncef Mohammed Slaoui
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20021116D0 publication Critical patent/NO20021116D0/no
Publication of NO20021116L publication Critical patent/NO20021116L/no
Publication of NO332800B1 publication Critical patent/NO332800B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/084—Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09C—RECLAMATION OF CONTAMINATED SOIL
    • B09C1/00—Reclamation of contaminated soil
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D3/00—Improving or preserving soil or rock, e.g. preserving permafrost soil
    • E02D3/11—Improving or preserving soil or rock, e.g. preserving permafrost soil by thermal, electrical or electro-chemical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Environmental & Geological Engineering (AREA)
  • Molecular Biology (AREA)
  • Structural Engineering (AREA)
  • Soil Sciences (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Mining & Mineral Resources (AREA)
  • Paleontology (AREA)
  • Civil Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Agronomy & Crop Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20021116A 1999-09-07 2002-03-06 Vaksinesammensetning egnet for behandling eller profylakse av humanpapillomavirusinfeksjoner og herpes simpleksvirusinfeksjoner NO332800B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9921146A GB9921146D0 (en) 1999-09-07 1999-09-07 Novel composition
PCT/EP2000/008784 WO2001017551A2 (en) 1999-09-07 2000-09-07 Combined vaccine compositions

Publications (3)

Publication Number Publication Date
NO20021116D0 NO20021116D0 (no) 2002-03-06
NO20021116L NO20021116L (no) 2002-04-30
NO332800B1 true NO332800B1 (no) 2013-01-14

Family

ID=10860520

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20021116A NO332800B1 (no) 1999-09-07 2002-03-06 Vaksinesammensetning egnet for behandling eller profylakse av humanpapillomavirusinfeksjoner og herpes simpleksvirusinfeksjoner
NO20033715A NO331825B1 (no) 1999-09-07 2003-08-21 HPV viruslignende partikkel samt vaksine
NO2012016C NO2012016I1 (no) 1999-09-07 2012-10-08 Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20033715A NO331825B1 (no) 1999-09-07 2003-08-21 HPV viruslignende partikkel samt vaksine
NO2012016C NO2012016I1 (no) 1999-09-07 2012-10-08 Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler

Country Status (33)

Country Link
US (3) US6936255B1 (cs)
EP (3) EP1769806A3 (cs)
JP (2) JP4689910B2 (cs)
KR (2) KR100594668B1 (cs)
CN (2) CN1325117C (cs)
AR (1) AR025502A1 (cs)
AT (2) ATE312624T1 (cs)
AU (1) AU766494B2 (cs)
BR (1) BR0014171A (cs)
CA (2) CA2443214C (cs)
CO (1) CO5280045A1 (cs)
CY (2) CY1107457T1 (cs)
CZ (2) CZ302811B6 (cs)
DE (2) DE60027029T2 (cs)
DK (2) DK1410805T3 (cs)
ES (2) ES2253636T3 (cs)
GB (1) GB9921146D0 (cs)
GC (1) GC0000201A (cs)
HK (1) HK1048435B (cs)
HU (2) HU229099B1 (cs)
IL (3) IL148456A0 (cs)
MX (1) MXPA02002484A (cs)
MY (2) MY142842A (cs)
NO (3) NO332800B1 (cs)
NZ (2) NZ517621A (cs)
PL (2) PL201264B1 (cs)
PT (1) PT1210113E (cs)
SG (1) SG110072A1 (cs)
SI (2) SI1210113T1 (cs)
TR (1) TR200200607T2 (cs)
TW (1) TWI258374B (cs)
WO (1) WO2001017551A2 (cs)
ZA (2) ZA200306402B (cs)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
AU750587B2 (en) * 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ES2284559T3 (es) * 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
DK1506222T3 (da) † 2002-05-17 2009-07-06 Univ Cape Town Kimæriske, humane papillomavirus16 L1-proteiner omfattende et L2-peptid, viruslignende partikler fremstillet deraf samt en fremgangsmåde til at fremstille partiklerne
CA2484941A1 (en) 2002-07-24 2004-02-05 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
WO2004024182A2 (en) 2002-09-13 2004-03-25 Intercell Ag Method for isolating hepatitis c virus peptides
CA2503693A1 (en) 2002-10-29 2004-05-13 Coley Pharmaceutical Group, Ltd. Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
KR101361769B1 (ko) * 2002-12-20 2014-02-10 글락소스미스클라인 바이오로지칼즈 에스.에이. Ｈｐｖ-16 ｌ1 ｖｌｐ 및 ｈｐｖ-18 ｌ1 ｖｌｐ 백신
SI1572233T1 (sl) * 2002-12-20 2011-07-29 Glaxosmithkline Biolog Sa Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
ES2562456T3 (es) * 2003-03-24 2016-03-04 Valneva Austria Gmbh Uso de un adyuvante que induce una respuesta inmune Th1 para mejorar las respuestas inmunes
CN100355453C (zh) * 2003-03-24 2007-12-19 英特塞尔股份公司 改进的疫苗
PE20060434A1 (es) * 2004-06-16 2006-06-08 Glaxosmithkline Biolog Sa Composicion inmunogenica que comprende plv o capsomeros de vph 16, vph 18 y al menos otro tipo de cancer de vph
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
CA2598079A1 (en) * 2005-02-16 2006-08-24 Novartis Vaccines And Diagnostics, Inc. Adjuvant composition comprising aluminium phosphate and 3d-mpl
JP4182074B2 (ja) 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
PE20061428A1 (es) * 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
SG159529A1 (en) * 2005-04-26 2010-03-30 Glaxosmithkline Biolog Sa Vaccine
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
MX338626B (es) 2005-12-29 2016-04-26 Boehringer Ingelheim Vetmed Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
US20090246220A1 (en) 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
KR101378872B1 (ko) 2006-09-26 2014-04-11 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 합성 애주번트를 함유하는 백신 조성물
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CN101622008A (zh) 2007-03-09 2010-01-06 默克公司 乳头瘤病毒疫苗组合物
ES2688474T3 (es) * 2007-06-26 2018-11-02 Japan Health Sciences Foundation Antígeno vacuna capaz de inducir anticuerpos de reacción cruzada y neutralizante contra el virus del papiloma humano del tipo de alto riesgo
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
JP5511660B2 (ja) 2008-06-04 2014-06-04 一般財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
HRP20141063T1 (hr) * 2008-07-31 2015-01-02 Glaxosmithkline Biologicals S.A. Cjepivo protiv hpv
CN102458463B (zh) 2009-05-22 2017-01-18 健诺西生物科学公司 针对ⅱ型单纯疱疹病毒的疫苗：诱发免疫应答的组合物和方法
SI2437753T1 (sl) 2009-06-05 2016-12-30 Infectious Disease Research Institute Sintetični glukopiranozil-lipidni adjuvansi in cepivni sestavki, ki jih vsebujejo
MX2011013566A (es) 2009-06-19 2012-06-28 Eyegene Inc Vacunas para cancer cervical.
CN102497880A (zh) * 2009-06-25 2012-06-13 葛兰素史密丝克莱恩生物有限公司 新的人乳头状瘤病毒(hpv)蛋白构建体及其在预防hpv疾病中的用途
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
EP2575878B1 (en) * 2010-05-28 2018-06-13 Zoetis Belgium S.A. Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
EP2609428B1 (en) * 2010-08-27 2016-02-10 Intervet International B.V. Potency test for vaccine formulations
CN102008721A (zh) * 2010-11-16 2011-04-13 浙江大学 一种hpv多肽/dc混合疫苗及其制备
CA2856697A1 (en) 2010-11-24 2012-06-07 Genocea Biosciences, Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
AU2012243039B2 (en) 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102210858B (zh) * 2011-05-18 2013-05-08 北京科兴生物制品有限公司 一种肠道病毒71型与甲型肝炎联合疫苗
KR102049988B1 (ko) * 2011-06-24 2019-11-28 머크 샤프 앤드 돔 코포레이션 알루미늄 아주반트를 포함하는 hpv 백신 제제 및 그의 제조 방법
EP2726097A4 (en) 2011-07-01 2015-03-11 Univ California HERPES VIRUS VACCINE AND METHOD OF USE
JP6199878B2 (ja) 2011-11-23 2017-09-20 ジェノセア バイオサイエンシーズ， インコーポレイテッド 単純ヘルペスウイルス２型に対する核酸ワクチン：免疫応答を誘発する組成物及び方法
CN110339160A (zh) 2012-02-07 2019-10-18 传染性疾病研究院 包含tlr4激动剂的改进佐剂制剂及其使用方法
PT2850431T (pt) 2012-05-16 2018-07-23 Immune Design Corp Vacinas para hsv-2
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
EP3711768A1 (en) 2013-04-18 2020-09-23 Immune Design Corp. Gla monotherapy for use in cancer treatment
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B2 (en) 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
US10953108B2 (en) 2016-08-01 2021-03-23 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
US10350288B2 (en) 2016-09-28 2019-07-16 Genocea Biosciences, Inc. Methods and compositions for treating herpes
CN107987159B (zh) * 2017-11-28 2021-06-22 上海药明生物医药有限公司 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
BR112021023726A2 (pt) 2019-05-25 2022-02-15 Infectious Disease Res Inst Composição e método para secagem por pulverização de uma emulsão de vacina adjuvante
CN110576034B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复方法
CN110652980B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复剂
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
CN114681602B (zh) * 2020-12-25 2023-12-01 中国食品药品检定研究院 一种双价人乳头瘤病毒疫苗
CN114796479B (zh) * 2022-06-02 2026-02-10 金宇保灵生物药品有限公司 一种畜类动物疫苗用水包油包水佐剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085804B2 (ja) 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE69233639T2 (de) * 1991-07-19 2007-05-31 Csl Ltd., Parkville Polynukleotidabschnitt des HPV16-Genoms
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
SG48309A1 (en) * 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
WO1996026277A1 (en) * 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
EP0877809A1 (en) * 1996-01-26 1998-11-18 Innogenetics N.V. TOXOPLASMA GONDII ANTIGEN Tg20
ES2301175T3 (es) * 1996-02-09 2008-06-16 Smithkline Beecham Biologicals S.A. Vacunas contra el producto del gen 63 del virus de la varicela zoster.
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
DE69933200T2 (de) * 1998-03-09 2007-02-22 Glaxosmithkline Biologicals S.A. Kombinierte impfstoffzusammensetzungen
US6500284B1 (en) 1998-06-10 2002-12-31 Suraltech, Inc. Processes for continuously producing fine grained metal compositions and for semi-solid forming of shaped articles
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
AU750587B2 (en) 1998-10-16 2002-07-25 Smithkline Beecham Biologicals (Sa) Adjuvant systems and vaccines
KR20010093290A (ko) * 1999-02-05 2001-10-27 폴락 돈나 엘. 사람 파필로마바이러스 백신 제제
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
WO2001017551A2 (en) 2001-03-15
CZ302811B6 (cs) 2011-11-23
TR200200607T2 (tr) 2002-06-21
US20060280756A1 (en) 2006-12-14
HK1064958A1 (en) 2005-02-08
US7101560B2 (en) 2006-09-05
US6936255B1 (en) 2005-08-30
KR100557665B1 (ko) 2006-03-06
DE60027029D1 (de) 2006-05-18
WO2001017551A3 (en) 2001-09-27
NO2012016I1 (no) 2012-10-15
TWI258374B (en) 2006-07-21
EP1410805B1 (en) 2005-12-14
DE60024893T2 (de) 2006-07-06
US20040126394A1 (en) 2004-07-01
CA2443214C (en) 2006-03-21
HUP0202804A2 (hu) 2002-12-28
HUP0202804A3 (en) 2004-08-30
MY130084A (en) 2007-05-31
HU0303215D0 (en) 2003-11-28
MXPA02002484A (es) 2002-08-28
CZ2002843A3 (cs) 2002-08-14
PL201264B1 (pl) 2009-03-31
US7220551B2 (en) 2007-05-22
SI1210113T1 (sl) 2006-08-31
CN100389824C (zh) 2008-05-28
AU766494B2 (en) 2003-10-16
NZ527560A (en) 2004-12-24
BR0014171A (pt) 2002-05-21
CA2443214A1 (en) 2001-03-15
CY1107457T1 (el) 2012-12-19
HK1048435A1 (en) 2003-04-04
AU7775100A (en) 2001-04-10
HU229099B1 (en) 2013-07-29
AR025502A1 (es) 2002-11-27
ATE312624T1 (de) 2005-12-15
NO20021116D0 (no) 2002-03-06
PL354039A1 (en) 2003-12-15
SG110072A1 (en) 2005-04-28
NO20021116L (no) 2002-04-30
ATE321569T1 (de) 2006-04-15
ES2253636T3 (es) 2006-06-01
IL158107A0 (en) 2004-03-28
EP1769806A2 (en) 2007-04-04
MY142842A (en) 2011-01-14
CN1387443A (zh) 2002-12-25
KR100594668B1 (ko) 2006-06-30
JP4689910B2 (ja) 2011-06-01
CA2384064A1 (en) 2001-03-15
SI1410805T1 (sl) 2006-04-30
NO331825B1 (no) 2012-04-10
CN1325117C (zh) 2007-07-11
NZ517621A (en) 2003-09-26
DK1410805T3 (da) 2006-04-18
DE60027029T2 (de) 2006-10-19
DK1210113T3 (da) 2006-07-03
GB9921146D0 (en) 1999-11-10
JP2004067696A (ja) 2004-03-04
HU228687B1 (en) 2013-05-28
CA2384064C (en) 2010-06-01
PT1210113E (pt) 2006-07-31
ZA200201810B (en) 2004-05-26
CY1106090T1 (el) 2011-06-08
ZA200306402B (en) 2004-08-02
CN1618465A (zh) 2005-05-25
HK1048435B (en) 2007-01-05
EP1769806A3 (en) 2007-10-24
GC0000201A (en) 2006-03-29
IL148456A0 (en) 2002-09-12
EP1210113A2 (en) 2002-06-05
HUP0303215A3 (en) 2008-04-28
TW200408405A (en) 2004-06-01
EP1410805A1 (en) 2004-04-21
PL201767B1 (pl) 2009-05-29
JP2003508495A (ja) 2003-03-04
KR20020027630A (ko) 2002-04-13
DE60024893D1 (de) 2006-01-19
KR20030087081A (ko) 2003-11-12
NO2012016I2 (no) 2012-10-08
CO5280045A1 (es) 2003-05-30
IL158107A (en) 2008-11-03
NO20033715D0 (no) 2003-08-21
ES2261243T3 (es) 2006-11-16
NO20033715L (no) 2002-04-30
EP1210113B1 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
CA2384064C (en) Vaccine against herpes simplex virus and human papilloma virus
US6451320B1 (en) Combined hepatitis and herpesvirus antigen compositions
AU765245B2 (en) Novel composition
AU2003236490B2 (en) Novel composition
HK1107519A (en) Vaccine against hpv
HK1099204A (en) Vaccine against hbv and hpv

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees